FDA & Clinical Trials
-
Inside the inMIND Trial Data Behind Minjuvi’s New PBS Listing
Specialised Therapeutics (ST), a Singapore-headquartered specialty pharmaceutical company, announced in a press release on August 2 that Minjuvi (tafasitamab), used together with rituximab and lenalidomide, is now reimbursed under Australia’s Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL). For patients, the listing means government-subsidized access to a chemotherapy-free treatment…
-
What Is Real-World Evidence? How Data Outside Clinical Trials Is Reshaping FDA Decisions
For decades, the randomized controlled clinical trial was the only currency the FDA accepted as proof of a drug’s safety and efficacy. That is changing. Real-world evidence — data generated outside the traditional clinical trial setting, from sources like electronic health records, insurance claims, and patient registries — is increasingly being used to support FDA…
-
What Is a Clinical Hold? When the FDA Stops a Trial and What Happens Next
Few announcements strike more fear into biotech investors than a clinical hold. When the FDA issues a clinical hold on a company’s Investigational New Drug application, it means the agency has identified concerns serious enough to stop human testing — either entirely or in part. Stocks frequently fall 30% to 60% or more on clinical…
-
What Is Fast Track Designation? The FDA’s Most Common Expedited Program Explained
Of all the FDA expedited designations a biotech company can receive, Fast Track Designation is the most commonly granted and, as a result, the least dramatic in terms of immediate stock impact. Yet it is one of the most practically useful regulatory tools available to drug developers, and understanding what it does — and critically,…
-
What Is Accelerated Approval? The FDA Pathway That Gets Drugs to Patients Faster
Accelerated Approval is one of the FDA’s most powerful and most debated regulatory tools. It allows drugs to be approved and reach patients before the company has generated the full clinical evidence that would normally be required — based on the premise that for serious conditions with unmet needs, earlier access to a promising therapy…
-
What Is Orphan Drug Designation? The FDA Program That Transformed Rare Disease Drug Development
For investors in clinical-stage biotech companies, few regulatory announcements are as consistently positive as an Orphan Drug Designation from the FDA. The designation signals that a drug targets a rare disease — a condition affecting fewer than 200,000 Americans — and that the company developing it is eligible for a suite of financial incentives and…
-
What Is a Complete Response Letter (CRL)? The FDA’s Most Feared Document Explained
The three letters that biotech investors most dread seeing on a PDUFA date are CRL. A Complete Response Letter from the FDA means the agency has reviewed the drug application and determined it cannot be approved as submitted. Stocks routinely fall 40%, 60%, or more on the day a CRL is announced. But a CRL…
-
What Are Clinical Trial Phases? Phase 1, 2, and 3 Explained for Investors
When a biotech company announces results from a Phase 2 trial or says it is initiating a Phase 3 study, that language carries specific and important meaning. Clinical trial phases are a defined regulatory framework — not marketing language — and each phase represents a distinct step in the process of proving a drug is…
-
What Is Breakthrough Therapy Designation? FDA’s Accelerated Path Explained
When the FDA grants a biotech company Breakthrough Therapy Designation for a drug, the market typically reacts immediately — and often positively. The designation is a signal from one of the world’s most respected regulatory agencies that a drug shows early evidence of substantial improvement over existing therapies for a serious condition. For investors in…
-
What Is a PDUFA Date? The FDA Milestone Every Biotech Investor Should Know
The PDUFA date is one of the most closely watched events on any biotech investor’s calendar. When the FDA sets one for a drug under review, it marks the day the agency has committed to issuing a decision — and the entire market pays attention. A stock can move 30%, 50%, or more in a…